Valuation: Zymeworks Inc.

Market Cap 2.17B 1.95B 1.79B 1.63B 3.09B 204B 3.17B 21.49B 8.56B 109B 8.15B 7.98B 345B P/E 2026 *
28.6x
P/E 2027 * 30.3x
Enterprise Value 1.93B 1.73B 1.6B 1.45B 2.75B 181B 2.82B 19.13B 7.62B 97.09B 7.25B 7.1B 307B EV / Sales 2026 *
6.3x
EV / Sales 2027 * 5.2x
Free-Float
92.01%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Zymeworks Inc.

1 day+2.11%
1 week+4.41%
Current month+9.96%
1 month+21.99%
3 months+30.22%
6 months+31.69%
Current year+19.48%
1 week 28.4
Extreme 28.4
31.97
1 month 24.6
Extreme 24.6
31.97
Current year 21.52
Extreme 21.52
31.97
1 year 18.2
Extreme 18.2
31.97
3 years 7.13
Extreme 7.13
31.97
5 years 4.11
Extreme 4.11
31.97
10 years 4.11
Extreme 4.11
59.03
Manager TitleAgeSince
Chief Executive Officer 64 05/01/2022
Director of Finance/CFO 44 01/04/2026
Chief Tech/Sci/R&D Officer 46 09/04/2026
Director TitleAgeSince
Chairman 64 05/01/2022
Director/Board Member 62 01/06/2019
Director/Board Member 52 01/03/2020
Date Insider Type Main position Quantity % Market Cap. Importance
9/10/26 Exercice

Chief Technology Officer

87,906 0.1239%
6/7/26 Free

Chief Operating Officer

939 0.0013%
13/5/26 Free

EVP, General Counsel

297,000 0.4027%
Change 5-day change 1-year change 3-year change Capi.($)
+2.11%+4.41%+74.29%+331.55% 2.17B
+0.01%+11.10%+60.83%+70.43% 68.32B
+1.22%+9.56%+15.97%+90.23% 60.26B
+0.24%+1.35%+23.78%+97.55% 55.86B
+1.60%+19.44%+28.80%+112.95% 48.43B
-1.32%+4.78%+29.15%+40.40% 45.34B
-3.54%-0.60%+207.76%+879.50% 41.76B
-3.33%+6.90%+22.78%+48.07% 34.5B
-2.19%-3.71%+90.94%+66.33% 33.8B
-1.37%+1.37%+47.35%+0.37% 25.96B
Average -0.65%+5.30%+60.17%+173.74% 42B
Weighted average by Cap. -0.63%+5.25%+55.45%+154.55%

Financials

2026 *2027 *
Net sales 307M 275M 254M 230M 436M 28.76B 448M 3.04B 1.21B 15.41B 1.15B 1.13B 48.71B 370M 332M 306M 278M 526M 34.73B 541M 3.67B 1.46B 18.61B 1.39B 1.36B 58.82B
Net income 66.98M 60.07M 55.36M 50.28M 95.15M 6.28B 97.81M 663M 264M 3.36B 251M 246M 10.64B 131M 117M 108M 98.33M 186M 12.28B 191M 1.3B 517M 6.58B 492M 481M 20.8B
Net Debt -239M -214M -198M -179M -340M -22.41B -349M -2.37B -942M -12.01B -897M -878M -37.95B -247M -222M -204M -185M -351M -23.16B -361M -2.44B -974M -12.41B -927M -907M -39.22B
Projected Income Statement - Annual - Zymeworks Inc.
Logo Zymeworks Inc.
Zymeworks Inc. is a global biotechnology company building a diversified portfolio of healthcare assets. The Company's asset and royalty aggregation strategy combines a portfolio of commercial and near-commercial assets, including YUPELRI (revefenacin), with a differentiated internal research and development engine. The Company's portfolio also includes Ziihera (zanidatamab-hrii), a HER2-targeted bispecific antibody discovered and developed by it and commercialized through global partnerships with Jazz Pharmaceuticals and BeOne Medicines, and pasritamig, a clinical-stage multispecific antibody developed by Johnson & Johnson using the Company's proprietary antibody engineering technologies. The Company is advancing a diverse pipeline of novel biotherapeutics, leveraging its proprietary Azymetric platform and expertise in antibody-drug conjugates, multispecific antibodies and other next-generation antibody technologies. Its product candidates include ZW191, ZW251, ZW220, ZW209 and ZW1528.
Employees
231
Date Price Change Volume
10/11/26 US$31.46 +2.11% 1,687,594
09/11/26 US$30.81 +3.98% 1,164,338
06/11/26 US$29.63 +3.11% 907,970
05/11/26 US$28.74 -7.13% 1,224,319
04/11/26 US$30.94 +2.69% 1,046,410
Trader
Investor
Global
Quality
ESG MSCI
BB
MarketScreener Ratings - Zymeworks Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
31.46USD
Average target price
41.93USD
Spread / Average Target
+33.28%
  1. Stock Market
  2. Stocks
  3. ZYME Stock